海和药物是中国领先的自主创新生物技术公司，专注于抗肿瘤创新药物的发现、开发、生产及商业化，为全球癌症患者带来挽救生命的疗法。
Location: China, Pudong
Employees: 201-500
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | 3H Health ... | 3hhinvestm... |
| - | Warburg Pi... | warburgpin... |
Mentions in press and media 2
| Date | Title | Description |
| 24.06.2024 | Kaiwa Pharmaceutical Co., Ltd. Obtained manufacturing and sales approval for MET inhibitor “Hi-Etan (R) Tablets 50mg” for unresectable advanced/recurrent non-small cell lung cancer positive for MET ge... | [Kaiwa Pharmaceutical Co., Ltd.] MET inhibitor “Hi-Etan(R)” Obtained manufacturing and sales approval for “Tablet 50mg” for unresectable advanced/recurrent non-small cell lung cancer positive for MET gene exon 14 skipping mutation *View in ... |
| 12.02.2019 | Hillhouse Capital endorses China-based HaiHe Biopharma's cancer pipeline in $146M round | Count HaiHe Biopharma in the new generation of Chinese biotechs answering the clarion call for homegrown innovation. The Shanghai-based drugmaker is emerging from relative obscurity with a $146 million round and the... |